-Reuters
BioVie Highlights Encouraging NE3107 Data In Parkinson’s, Alzheimer’s Trials
BioVie Inc (NASDAQ:BIVI) announced results from two Phase 2 trials assessing NE3107’s potential in Parkinson’s Disease (PD) and Alzheimer’s Disease (AD).…
Related Posts
$1000 Invested In This Stock 20 Years Ago Would Be Worth $13,000 Today
Canadian Pacific Kansas (NYSE:CP) has outperformed the market over the past 20 years by 6.23% on an annualized…
BMO Capital Maintains Outperform on Spartan Delta, Raises Price Target to C$19
BMO Capital analyst Mike Murphy maintains Spartan Delta (TSX:SDE) with a Outperform and raises the price target from C$18 to C$19.
Reported Late Tuesday April 11, Amtech Systems Receives Multiple Orders For High Temperature Clustered 300mm Horizontal Diffusion Systems Valued At $9.7M And Will Ship Mid FY24
Amtech Systems, Inc. (NASDAQ:ASYS), a manufacturer of capital equipment, including thermal processing, wafer polishing, cleaning and related consumables and services used in fabricating semiconductor devices, such as